Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Sanraku-ocean Co., Ltd.

Other

Nippon Kayaku Kabushiki Kaisha

Yamanouchi Pharmaceutical Company Ltd.

Microbial Chemistry Research Foundation

Bristol-myers Company

Banyu Pharmaceutical Co. Ltd

Kanegafuchi Kagaku Kogyo Kabushiki Kaisha

Meiji Seika Kaisha, Ltd.

Hokko Chemical Industry Co., Ltd.

Mercian Corporation

Taiho Pharmaceutical Company Limited

Kirin Beer Kabushiki Kaisha

Kanegafuchi Chemical Industry Co., Ltd.

Tomio Takeuchi

Hamao Umezawa

Masa Hamada

Takaaki Aoyagi

Hiroshi Naganawa

Masaaki Ishizuka

Shinichi Kondo

Toshikazu Oki

Sumio Umezawa

Tsutomu Tsuchiya

Taiji Inui

Hironobu Iinuma

Akihiro Yoshimoto

Tsutomu Sawa

Tomoyuki Ishikura

Teruya Nakamura

Akira Takamatsu

Yasuhiko Muraoka

Daishiro Ikeda

Akio Fujii

Rokuro Okamoto

Yasushi Takagi

Shuichi Sakamoto

Kunio Isshiki

Shuichi Gomi

Kuniaki Tatsuta

Hajime Morishima

Akihiro Tanaka

Takeo Yoshioka

Shunzo Fukatsu

Kenji Maeda

Tetsushi Saino

Tomohisa Takita

Yoshikazu Takahashi

Hiroshi Tone

Makoto Tsuda

Ikuo Matsumoto

Hamao Umezawa, Deceased

Seiji Shibahara

Yoshiaki Takahashi

Mitsugu Hachisu

Hiroo Hoshino

Toshiharu Nagatsu

Kazuo Umezawa

Yoshio Watanabe

Katsutoshi Takahashi

Masaji Sezaki

Nobuyoshi Shimada

Yoshiro Okami

Yoshihisa Umeda

Kageaki Kouno

Haruo Yamamoto

Norio Shibamoto

Atsushi Takahashi

Masatoshi Abe

Takashi Nakashima

Yoshihide Fuse

Eiki Shitara

Masayuki Igarashi

Toshio Tsuchida

Atsushi Tamura

Fuminori Abe

Rinzo Nishizawa

Yoshiyuki Koyama

Keiji Ogawa

Masashi Yoshida

Toshiaki Kudo

Hiroshi Yoshikawa

Yasuharu Sekizawa

Osamu Tanabe

Takayuki Usui

Yuichi Kita

Junji Yoshizawa

Tetsuya Mori

Naoki Matsumoto

Donald W Kufe

Kiyoshi Watanabe

Masakazu Fukushima

Ralph R Weichselbaum

Masao Yamamoto

Hideaki Takahashi

Takayoshi Hidaka

Hideki Hashizume

Hideo Sugimura

Tsuneo Okonogi

Yoshihiko Kobayashi

Ken Nishihata

Tadayoshi Shiraishi

Shigeharu Inoue

Munekazu Iinuma

Yasushi Takahashi

Toshiaki Miyake

Shohachi Nakajima

Hidenori Iwamoto

Yusuke Wataya

Hiroyuki Kawai

Hye-Sook Kim

Hiroyuki Inoue

Naoto Kawamura

Tomohiro Sameshima

By culturingsp. BMK333-48F3 (deposit number of FERM BP-7477), an antibiotic, tripropeptin Z, tripropeptin A, tripropeptin B, tripropeptin C or tripropeptin D represented by the general formula (I): wherein R is 7-methyl-octyl group, 8-methyl-nonyl group, 9-methyl-dodecyl group, 10-methyl-undecyl group or 11-methyl-dodecyl group, is obtained as antibiotics having excellent antibacterial activities against bacteria and having a novel molecular structure. These tripropeptins each have an excellent antibacterial activity against various bacteria and drug-resistant strains thereof, such as methicillin-resistant strains and vancomycin-resistant strains.

Antibiotics, tripropeptins and process for producing the same

A medicament for prophylaxis or treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes, which comprise as an active ingredient a sulphostin-related compound represented by general formula (I): wherein n is an integer of 0 to 3, or a pharmacologically acceptable salt thereof.

Medicament for treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes

Provided are novel processes for the efficient production of L-epi-2-inosose and epi-inositol which are useful either as various medicines or intermediates for the syntheses of various medicines. In the processes, inexpensive myo-inositol is used as a starting compound which is reacted with a gram-negative bacterium capable of converting myo-inositol into L-epi-2-inosose, and thereby producing L-epi-2-inosose by conversion of myo-inositol into L-epi-2-inosose. A biologically pure culture ofsp. AB 10215 strain is also provided which has a characteristic nature of being capable of converting myo-inositol into L-epi-2-inosose.

Process for producing L-epi-2-inosose and novel process for producing epi-inositol using microorganisms

A compound represented by formula (I); a process for producing a compound (substance F-1490) of formula (I), wherein X represents &#x2014;O&#x2014; and R represents a hydroxyl group, by using a microorganism belonging to the genus; and asp. F-1490 strain (FERM BP-8287) capable of producing the substance F-1490; and an osteoclast differentiation inhibitory agent containing as an active ingredient the compound represented by formula (I): wherein X represents &#x2014;O&#x2014; or &#x2014;CH&#x2014;, and R represents a hydroxyl group when X represents &#x2014;O&#x2014;, or a hydrogen atom when X represents &#x2014;CH&#x2014;.

Osteoclast differentiation inhibitors

An antibiotic SF2487 substance having the formula (I)or a salt thereof possesses an antimalarial activity against the proliferation of malarial parasites and is therefore useful as an antimalarial drug.

Compositions for treating or preventing malaria and method of treating malaria

A compound of the formula (I):and a compound of the formula (V):as well as a compound of the formula (X):which are each a novel siastatin B derivative having a potent inhibitory activity against a glycosidase, are now synthesized by new processes. The compound of the formula (I), the compound of the formula (V) and the compound of the formula (X) have a potent enzyme-inhibitory activity to a glycosidase, which is particularly N-acetyl-galactosaminidase, galactosidase, glucosidase and mannosidase.

Siastatin B derivatives having a glycosidase inhibitory activity and processes for producing the same

Provided are novel processes for the efficient production of L-epi-2-inosose and epi-inositol which are useful either as various medicines or intermediates for the syntheses of various medicines. In the processes, there is used inexpensive myo-inositol as a starting compound. That is, there is now developed a new process which comprises reacting myo-inositol with a gram-negative bacterium capable of converting myo-inositol into L-epi-2-inosose, and thereby producing L-epi-2-inosose by conversion of myo-inositol into L-epi-2-inosose. Further, a novel process is provided, which comprises reacting the so produced L-epi-2-inosose with a reducing agent made of an alkali metal boron hydride or any other alkali metal hydride in an aqueous reaction medium, to produce epi-inositol and myo-inositol, and then isolating epi-inositol from the resulting reaction product composed of the epi-inositol and myo-inositol.

Process for producing L-epi-2-inosose and novel process for producing epi-inositol

Antibiotic caprazamycins and process for producing the same

2-n-substituted or unsubstituted-2-amino-5-methylpiperidine-3,4-diols and processes for the preparation thereof

Benzofurylpyrone derivatives

A method for enhancing the efficacy of chemotherapy and/or radiation in the treatment of cancer in animals, particularly humans, is provided wherein certain isocoumarin derivatives which exhibit unique radiosensitization activity and/or chemopotentiation properties are employed in a combination treatment with ionizing radiation and/or chemotherapy.

Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives

Sulphostin analogue and process for producing sulphostin and its analogue

Salicylamide derivatives represented by formulae ( ) and ( ); intermediates in the production thereof; a process for producing the same; and drugs containing the same as the active ingredient. The salicylamide derivatives represented by formulae ( ) and ( ) are useful as anti-inflammatory agents and immunosuppressive agents which exert an effect of inhibiting the activation of NF-&kgr;B with little side effects.

Salicylamide derivatives

Process for producing isocoumarins and intermediates for the same

20,23-disubstituted mycaminosyltylonolide derivatives and use of the same in the field of the prophylaxis and treatment of pasteurellosis are disclosed. The di-substituents are peperidino optionally substituted with one or two methyl groups. The derivatives have selective antibacterial activity against Pasteurella.

Macrolide antibiotics and treatment and prophylaxis of pasteurellosis using the same

Growing community of inventors

Tokyo, Japan

Tomio Takeuchi